These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 19279566)

  • 1. Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects.
    Smolander J; Vogt B; Maillard M; Zweiacker C; Littke T; Hengelage T; Burnier M
    Clin Pharmacol Ther; 2009 Jun; 85(6):628-34. PubMed ID: 19279566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avosentan is protective in hypertensive nephropathy at doses not causing fluid retention.
    Baltatu OC; Zaugg CE; Schumacher C; Louie P; Campos LA; Bader M
    Pharmacol Res; 2014 Feb; 80():9-13. PubMed ID: 24368192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of the ETA-selective endothelin receptor antagonist SPP301 in healthy human subjects.
    Dieterle W; Mann J; Kutz K
    J Clin Pharmacol; 2004 Jan; 44(1):59-66. PubMed ID: 14681342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of endothelin-1 and endothelin-1-receptor blockade on renal function in humans.
    Vuurmans JL; Boer P; Koomans HA
    Nephrol Dial Transplant; 2004 Nov; 19(11):2742-6. PubMed ID: 15328386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of congestive heart failure after treatment with an endothelin receptor antagonist.
    Hoekman J; Lambers Heerspink HJ; Viberti G; Green D; Mann JF; de Zeeuw D
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):490-8. PubMed ID: 24408122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of statins on renal sodium and water handling: acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans.
    Paulsen L; Holm C; Bech JN; Starklint J; Pedersen EB
    Nephrol Dial Transplant; 2008 May; 23(5):1556-61. PubMed ID: 18065809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avosentan for overt diabetic nephropathy.
    Mann JF; Green D; Jamerson K; Ruilope LM; Kuranoff SJ; Littke T; Viberti G;
    J Am Soc Nephrol; 2010 Mar; 21(3):527-35. PubMed ID: 20167702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease.
    Dhaun N; Ferro CJ; Davenport AP; Haynes WG; Goddard J; Webb DJ
    Nephrol Dial Transplant; 2007 Nov; 22(11):3228-34. PubMed ID: 17556408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absolute bioavailability and pharmacokinetics of avosentan in man.
    Dieterle W; Hengelage T
    Int J Clin Pharmacol Ther; 2009 Sep; 47(9):587-94. PubMed ID: 19761718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of SPP 301, an endothelin antagonist, on intraocular pressure in glaucomatous monkey eyes.
    Wang RF; Podos SM; Serle JB; Baltatu OC
    Curr Eye Res; 2011 Jan; 36(1):41-6. PubMed ID: 21174596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of food intake on the pharmacokinetics of avosentan in man.
    Dieterle W; Hengelage T
    Int J Clin Pharmacol Ther; 2008 Sep; 46(9):453-8. PubMed ID: 18793575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The distinct alterations produced in cardiovascular functions by prednisolone and nitro-prednisolone (NCX-1015) in the rat highlight a causal role for endothelin-1.
    Di Filippo C; Rossi F; Ongini E; Del Soldato P; Perretti M; D'Amico M
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1133-41. PubMed ID: 15113846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avosentan reduces albumin excretion in diabetics with macroalbuminuria.
    Wenzel RR; Littke T; Kuranoff S; Jürgens C; Bruck H; Ritz E; Philipp T; Mitchell A;
    J Am Soc Nephrol; 2009 Mar; 20(3):655-64. PubMed ID: 19144760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist.
    van Giersbergen PL; Bodin F; Dingemanse J
    Eur J Clin Pharmacol; 2002 Jul; 58(4):243-5. PubMed ID: 12136369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice.
    Watson AM; Li J; Schumacher C; de Gasparo M; Feng B; Thomas MC; Allen TJ; Cooper ME; Jandeleit-Dahm KA
    Diabetologia; 2010 Jan; 53(1):192-203. PubMed ID: 19862499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal haemodynamic and tubular actions of urotensin II in the rat.
    Abdel-Razik AE; Forty EJ; Balment RJ; Ashton N
    J Endocrinol; 2008 Sep; 198(3):617-24. PubMed ID: 18577565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure.
    Mitrovic V; Seferovic P; Dodic S; Krotin M; Neskovic A; Dickstein K; de Voogd H; Böcker C; Ziegler D; Godes M; Nakov R; Essers H; Verboom C; Hocher B
    Circ Heart Fail; 2009 Nov; 2(6):523-31. PubMed ID: 19919976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose vasopressin increases glomerular filtration rate, but impairs renal oxygenation in post-cardiac surgery patients.
    Bragadottir G; Redfors B; Nygren A; Sellgren J; Ricksten SE
    Acta Anaesthesiol Scand; 2009 Sep; 53(8):1052-9. PubMed ID: 19572935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin antagonists for diabetic and non-diabetic chronic kidney disease.
    Kohan DE; Pollock DM
    Br J Clin Pharmacol; 2013 Oct; 76(4):573-9. PubMed ID: 23228194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.